Unknown PHASE4 INTERVENTIONAL 2-arm NCT03912909

Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans (EMPA-SNS)

Effects of SGLT-2 Inhibition on Sympathetic Nervous System Activity in Humans

Sponsor: Royal Perth Hospital

Conditions Metabolic Syndrome Obesity Type 2 Diabetes Mellitus

Interventions Empagliflozin Oral Tablet [Jardiance] Placebo Oral Tablet

Updated 8 times since 2019 Last updated: Sep 28, 2022 Started: Aug 1, 2018 Primary completion: Mar 31, 2024 Completion: Dec 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Metabolic Syndrome and Obesity and is currently ongoing. Royal Perth Hospital leads this study, which shows 8 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Feb 2025 — Present [monthly]

Unknown PHASE4

Status: Recruiting → Unknown
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Oct 2022 — Jul 2024 [monthly]

Recruiting PHASE4
Oct 2021 — Oct 2022 [monthly]

Recruiting PHASE4

▶ Show 3 earlier versions

Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE4
Jul 2020 — Jan 2021 [monthly]

Recruiting PHASE4
May 2019 — Jul 2020 [monthly]

Recruiting PHASE4

First recorded

Aug 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Royal Perth Hospital

Data source: Royal Perth Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Perth, Australia